L.A. Decosterd

Discipline

Psychologie (2) Anthropologie biologique (1)

Type de document

Articles (54) Recensions (5) Colloques et conférences (3)

Type de document

Mémoires, Thèses et HDR (1)

Co-auteur

Date

Date

Source

Source

Mot-clé

Treatment (42) Human beings (34) plasma (32) Therapeutics (31) Patients (31) Patients (30) thérapie (29) Drug monitoring (23) Example (23) Pharmacokinetics (22) pharmacocinétique (21) modèle (21) exposition (21) Pharmacokinetics (21) dosage (20) Population (19) Drugs (19) Older people (19) Population (19) Management (16) surveillance (15) Monitoring (15) dose (14) Time (14) Analysis (14) temps (durée) (13) analyse (13) adulte (13) Use (13) Models (13)

Mot-clé

Development (1) Employment (1) Variation (1) Treatment (1) Clinical pharmacology (1) Sports records (1) Signs and symbols (1) Progress (1) Prediction theory (1) Mycoses (1) Miracles (1) Medical microbiology (1) Liquids (1) Licenses (1) International organization (1) Impact (1) High pressure (Technology) (1) High pressure (Science) (1) Evidence (1) Division (1) Communicable diseases (1) Clinics (1) Candida (1) Breast (1) Blood plasma (1) Athletic ability (1) Use studies (1) Use studies (1) Technique (1) Toxicology (1)

Documents écrit par L.A. Decosterd (57) | parle de L.A. Decosterd (1)

Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma.
J. Tachet et al. (15 nov. 2023)
Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study.
P. Thoueille et al. (27 sept. 2023)
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
P. Biniecka et al. (16 févr. 2023)
Development and validation of a liquid chromatography coupled to tandem mass spectrometry method for the monitoring of temsavir plasma concentrations in people living with HIV.
P. Thoueille et al. (1 janv. 2023)
Precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: A perspective.
M. Briki et al. (2023)
Treatment-emergent adverse events and antiseizure medication actual drug load.
T. Prétat et al.
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
E. Schmulenson et al.
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
P. Thoueille et al. (29 juil. 2022)
Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer.
P. Courlet et al. (21 juin 2022)
Development of an assay by liquid chromatography coupled to tandem mass spectrometry for thiopurines drugs in whole blood and application for their Therapeutic Drug Monitoring
N. Nguyen et al. (1 juin 2022)
Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation.
K. Dao et al. (2 févr. 2022)
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.
P. Thoueille et al. (2 févr. 2022)
Therapeutic drug monitoring of newer generation antiseizure medications at the point of treatment failure.
P. Fluckiger et al.
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
P. Courlet et al.
Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
F. Stader et al.
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
S. Alves Saldanha et al.
No renal dysfunction or salt and water retention in acute mountain sickness at 4,559 m among young resting males after passive ascent.
J. Biollaz et al. (1 janv. 2021)
Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID - imatinib study.
I.H. Bartelink et al. (2021)
Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
L.A. Decosterd et al. (10 nov. 2020)
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
D. Sculier et al.
Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.
P. Courlet et al.
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
P. Courlet et al.
Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers.
A.E. Schantl et al. (5 févr. 2020)
Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers.
K. Dao et al.
The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib
T. Buclin et al. (2020)

next
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods, [and] Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
A. Pascual (2010)